Benralizumab (Fasenra) has been approved for self-administration by patients and caregivers by the US FDA, according to AstraZeneca. The Fasenra Pen comes in a prefilled, single-use autoinjector.

Benralizumab is an antieosinophil humanized monoclonal antibody that selectively targets the interleukin-5 receptor expressed on the surface of eosinophils.

Since 2017, it has been available in the United States in a fixed-dose prefilled syringe for subcutaneous administration in a physician’s office as add-on maintenance treatment for adults and for children aged 12 years or older who have severe eosinophilic asthma.